/PRME
PRME Stock - Prime Medicine, Inc.
Healthcare|BiotechnologyNASDAQ
$3.64+1.11%
+$0.04 (+1.11%) • Dec 19
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.52
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.12
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+373.9%upside
Target: $17.25
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PRME
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.60 – $3.68
TARGET (TP)$17.25
STOP LOSS$3.35
RISK/REWARD1:46.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.71
52W High$6.94
52W Low$1.11
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.98M | N/A | N/A | N/A | $5.21M |
| Gross Profit | $2.98M | N/A | N/A | N/A | $2.23M |
| Gross Margin | 100.0% | N/A | N/A | N/A | 42.8% |
| Operating Income | $-202,467,000 | $-204,792,000 | $-116,544,000 | $-84,474,000 | $-932,000 |
| Net Income | $-195,882,000 | $-198,133,000 | $-121,821,000 | $-165,367,000 | $-3,410,000 |
| Net Margin | -6566.6% | N/A | N/A | N/A | -65.5% |
| EPS | $-1.65 | $-2.18 | $-1.46 | $-1.92 | $-0.05 |
Company Overview
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
59%
Hold / Neutral
7
41%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
10 Bullish7 Neutral/Bearish
Price Targets
$16
Average Target
↑ 335.0% Upside
Now
$2
Low
$16
Average
$27
High
Based on 15 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 27th 2025 | Citigroup | Downgrade | Neutral | $1.5 |
| May 20th 2025 | JP Morgan | Downgrade | Neutral | - |
| May 20th 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| December 10th 2024 | JMP Securities | Initiation | Mkt Outperform | $10 |
| May 20th 2024 | H.C. Wainwright | Initiation | Buy | $10 |
| May 16th 2024 | Citigroup | Upgrade | Buy | $10 |
| April 22nd 2024 | Chardan Capital Markets | Initiation | Buy | $17 |
| April 8th 2024 | TD Cowen | Initiation | Buy | - |
| April 3rd 2024 | Wedbush | Initiation | Outperform | $12 |
| January 16th 2024 | Stifel | Downgrade | Hold | $9← $18 |
| December 8th 2023 | Citigroup | Initiation | Neutral | $10 |
| October 9th 2023 | BMO Capital Markets | Initiation | Outperform | $19 |
| July 31st 2023 | Guggenheim | Initiation | Buy | $24 |
| April 18th 2023 | Stifel | Initiation | Buy | $18 |
| November 14th 2022 | Jefferies | Initiation | Buy | $25 |
Earnings History & Surprises
PRMEBeat Rate
31%
Last 13 quarters
Avg Surprise
-3.6%
EPS vs Estimate
Beats / Misses
4/9
Last 12 quarters
Latest EPS
$-0.32
Q4 2025
EPS Surprise History
Q1 24
-16.7%
$-0.56vs$-0.48
Q2 24
+2.2%
$-0.44vs$-0.45
Q3 24
-15.0%
$-0.46vs$-0.40
Q4 24
-2.3%
$-0.44vs$-0.43
Q1 25
+16.2%
$-0.31vs$-0.37
Q2 25
-25.0%
$-0.40vs$-0.32
Q3 25
-13.9%
$-0.41vs$-0.36
Q4 25
-14.3%
$-0.32vs$-0.28
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 27, 2026 | $-0.25 | — | — | — |
Q4 2025 | Nov 7, 2025 | $-0.28 | $-0.32 | -14.3% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.36 | $-0.41 | -13.9% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.32 | $-0.40 | -25.0% | ✗ MISS |
Q1 2025 | Feb 28, 2025 | $-0.37 | $-0.31 | +16.2% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.43 | $-0.44 | -2.3% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.40 | $-0.46 | -15.0% | ✗ MISS |
Q2 2024 | May 10, 2024 | $-0.45 | $-0.44 | +2.2% | ✓ BEAT |
Q1 2024 | Mar 1, 2024 | $-0.48 | $-0.56 | -16.7% | ✗ MISS |
Q4 2023 | Nov 3, 2023 | $-0.45 | $-0.55 | -22.2% | ✗ MISS |
Q3 2023 | Aug 7, 2023 | $-0.42 | $-0.47 | -11.9% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.42 | $-0.44 | -4.8% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $-0.65 | $-0.56 | +13.8% | ✓ BEAT |
Q4 2022 | Oct 21, 2022 | $-0.71 | $-0.38 | +47.1% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | — | $-0.50 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.42 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.86 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.32 | — | — |
Q2 2021 | Jun 30, 2021 | — | $0.05 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-11.82 | — | — |
Latest News
Prime Medicine Announced New England Journal Of Medicine Publication Of PM359 Clinical Data For Two Patients For Treatment Of Chronic Granulomatous Disease
📈 PositiveBenzinga•Dec 7, 2025, 10:28 PM
Citigroup Maintains Neutral on Prime Medicine, Lowers Price Target to $4.25
📉 NegativeBenzinga•Nov 11, 2025, 08:33 PM•Also:
Chardan Capital Maintains Buy on Prime Medicine, Lowers Price Target to $9
➖ NeutralBenzinga•Nov 10, 2025, 12:21 PM
Prime Medicine Filed $200M Mixed Shelf Offering for Sale of Common Stock From Time to Time
➖ NeutralBenzinga•Nov 7, 2025, 01:08 PM
Prime Medicine Expects That Its Cash, Cash Equivalents And Investments Of $213.3M As Of September 30, 2025 Will Be Sufficient To Fund Its Operating Expenses And Capital Expenditure Requirements Into 2027.
📈 PositiveBenzinga•Nov 7, 2025, 12:47 PM
Prime Medicine Q3 EPS $(0.32) Misses $(0.26) Estimate, Sales $1.225M Beat $1.026M Estimate
➖ NeutralBenzinga•Nov 7, 2025, 12:46 PM
Prime Medicine slides after pricing $125.4M stock offering
📉 NegativeSeeking Alpha•Jul 31, 2025, 03:51 AM
Prime Medicine announces public stock offering; shares down 11.5%
📉 NegativeSeeking Alpha•Jul 30, 2025, 08:20 PM
Prime Medicine soars as Jones sees it as an acquisition target
📈 PositiveSeeking Alpha•Jul 7, 2025, 04:33 PM
Prime Medicine drops after cutting CGD program amid restructuring
📉 NegativeSeeking Alpha•May 19, 2025, 02:00 PM
Frequently Asked Questions about PRME
What is PRME's current stock price?
Prime Medicine, Inc. (PRME) is currently trading at $3.64 per share. The stock has moved +1.11% today.
What is the analyst price target for PRME?
The average analyst price target for PRME is $17.25, based on 1 analyst.
What sector is Prime Medicine, Inc. in?
Prime Medicine, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PRME's market cap?
Prime Medicine, Inc. has a market capitalization of $0.64 billion, making it a small-cap company.
Does PRME pay dividends?
No, Prime Medicine, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBCAX
Bicara Therapeutics Inc. Common Stock
$17.60
Mkt Cap: $1.0B
EYPT
EyePoint Pharmaceuticals, Inc.
$17.43
Mkt Cap: $1.2B
KURA
Kura Oncology, Inc.
$9.84
Mkt Cap: $0.9B
MRVI
Maravai LifeSciences Holdings, Inc.
$3.43
Mkt Cap: $0.5B
PROK
ProKidney Corp.
$2.37
Mkt Cap: $0.3B
REPL
Replimune Group, Inc.
$9.88
Mkt Cap: $0.8B
RZLT
Rezolute, Inc.
$1.77
Mkt Cap: $0.2B
SEPN
Septerna, Inc.
$29.58
Mkt Cap: $1.3B
TYRA
Tyra Biosciences, Inc.
$25.51
Mkt Cap: $1.4B
VIR
Vir Biotechnology, Inc.
$5.76
Mkt Cap: $0.8B
Explore stocks similar to PRME for comparison